The Life Sciences Report
Notable Quotes
"BTI's Transcend platform is a huge financial incentive to the owner of the therapy because it could greatly extend the drug's exclusivity." (5/16/13) biOasis Technologies Inc. - The Life Sciences Report Interview with William Gregozeski More >
"ATHX is a neat little company that has a great management team and deep science bench." (5/10/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert More >
"MSLP was growing very fast, and it had significant events that made it possible for us to raise $12M for it." (4/25/13) MusclePharm Corp. - The Life Sciences Report Interview with Richard Huebner More >
"What's particularly exciting about VNRX is that it believes its technology is able to identify targeted cancers in stage 1 and stage 2." (4/25/13) VolitionRx Ltd. - The Life Sciences Report Interview with Dick Huebner More >
"ATHX's partnership with Pfizer Inc. puts it in a remarkable position." (4/11/13) Athersys Inc. - The Life Sciences Report Interview with Steve Brozak More >
Companies
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk High: | ||
Experts Commenting on This Company
|
Neuralstem Inc.TICKER: CUR:NYSE.MKTNeuralstem Inc. is focused on developing and commercializing treatments for central nervous system diseases based on transplanting human neural stem cells and small molecule drugs. The company has developed and maintains a portfolio of patents and patent applications that form the base of its research and development efforts in neural stem cell research, small molecule research and related technologies. Neuralstem has also developed and patented a series of small molecule compounds (low molecular weight organic compounds) that can efficiently cross the blood/brain barrier. |
The information provided below is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Expert Comments:
Jason Napodano, Zacks Investment Research (5/13/13) "We continue to be optimistic on the Neuralstem Inc. story; NSI-566 is currently being studied in amyotrophic lateral sclerosis, spinal cord injury and ischemic stroke, all significant unmet medical needs and enormous market opportunities. The company is well-funded, with several clinical catalysts on the horizon for NSI-566 and NSI-189; our rating is Outperform with a $2.50 price target." -Zacks Investment Research
Larry Smith, Seeking Alpha (5/7/13) "I am continuing to recommend purchase of Neuralstem Inc. The company has completed its first trial in humans, a 15-patient phase 1 trial in amyotrophic lateral sclerosis. Results of this trial have indicated that the surgical procedure used to implant the cells and the cells themselves are safe, which is the critical first step."
Raghuram Selvaraju, Aegis Capital Corp. (4/17/13) "Neuralstem Inc. received approval from the FDA to begin phase 2 testing of its neural stem cell line therapeutic, designated NSI-566, in patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. . .this is a significant step forward for the company and could represent a substantial value driver in the future if NSI-566 is able to demonstrate meaningful clinical benefit. . .as a result of the excellent safety and tolerability demonstrated in phase 1 testing, Neuralstem will now be able to proceed more aggressively in phase 2 development."
Jason Napodano, Zacks Small-Cap Research (3/15/13) "We continue to be positive on the Neuralstem Inc. story. We believe the company's dual-technology platform focused on cell therapy and traditional pharmaceutical products provides investors with the best of both worlds: An early-stage investment in a potentially revolutionary pipeline in regenerative medicine and an attractive and undervalued small-molecule pipeline we think is sure to attract interest from larger pharmaceutical partners given the novel mechanism of action and broad application potential into multiple indications."
The Life Sciences Report interview with Ram Selvaraju (2/14/13) "Neuralstem Inc. has gone from strength to strength recently. It had a phenomenal year in 2012. One of the watershed events for the company was the publication of a landmark Cell paper discussing its technology platform and its lead cell therapy candidate, NSI-566 (human spinal cord stem cells), which demonstrated the ability to completely regrow damaged spinal cords in rats. This has never been seen before. On top of that, the company reported additional safety and anecdotal efficacy data from an ongoing phase 1/2 study in amyotrophic lateral sclerosis (ALS), which it is also addressing with its NSI-566 cell line. ALS is a massive unmet need. . .if Neuralstem's cells turn out to have even a minor impact on functional independence or motor function in the context of ALS patients, it could very easily be fast-tracked toward approval, even if the patient data set is relatively small. The company finished an 18-patient phase 1/2 study in ALS, and now it wants to go to the FDA and potentially get approval to start a pivotal phase 3 study with 50–60 patients. Potentially, this trial could kick off well before the end of this year.
"Finally, and perhaps most exciting, is that the company announced on Jan. 14 that it had received approval from the FDA to begin a phase 1 trial using its NSI-566 cells in the context of spinal cord injury. . .it is very encouraging that the FDA gave Neuralstem such timely approval to start this trial. The company could potentially generate efficacy data in spinal cord injury by the end of this year. If that turns out to be successful, we think Neuralstem could apply for rapid access to the market because there is currently nothing out there to help spinal cord injury patients." More >
